1 / 52

Acute Myocardial Infarction (Acute MI)

Acute Myocardial Infarction (Acute MI). Prof. Arthur Pollak, M.D. Director, Acute Cardiac Care Center Director of Clinical Research Heart Institute Hadassah – Hebrew University Medical Center. Atherosclerosis is a Generalized Disease.

ilya
Télécharger la présentation

Acute Myocardial Infarction (Acute MI)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Acute Myocardial Infarction(Acute MI) Prof. Arthur Pollak, M.D. Director, Acute Cardiac Care Center Director of Clinical Research Heart Institute Hadassah – Hebrew University Medical Center

  2. Atherosclerosis is a Generalized Disease

  3. Comparison of Age at First Myocardial Infarction Among Women and Men Across Geographic Regions Yusuf S: The INTERHEART Study. Lancet 2004;364:937

  4. Age distribution in Hadassah CCU

  5. RISK FACTORS FOR CAD %

  6. NUMBER OF CORONARY ARTERIES OCCLUDED > 80% NUMBER OF CORONARY ARTERIES INVOLVED

  7. The Effect of Race & Sex on Physicians’ Recommendations for Cardiac Catheterization Referral for Catheterization Race & sex influence how physicians interpret & managechest pain Schulman KA, et al. NEJM 1999;340:618-616

  8. Atheroma Morphology by Ultrasound “Soft” Lipid-Laden Plaque “Hard” Fibrous Plaque

  9. Plaque Rupture

  10. Acute coronary syndromes

  11. The Normal Heart Acute anterior wall MI

  12. Recent large Antero-Septal Myocardial Infarction

  13. Ebers Papyrus

  14. Clinical Presentation • Typical Chest Pain • pressure, heaviness, burning • irradiation to arms, neck, jaw, upper abdomen, sometimes to the back • Shortness of breath • pulmonary congestion → pulmonary edema • Nausea, Vomiting • Cold sweating • Dizziness → look for arrhythmias • Anxiety, fear of death (!) • Obtain ECG as quickly as possible (< 10 min) !

  15. Physical examination • Pallor • Cold and clammy extremities • Cold sweat on forehead and palms • Bilateral crackles / crepitations / rales on lung auscultation (mostly basal) • Muffled heart sounds, sometimes S4 • Apical systolic murmur → look for mitral regurgitation • Pulse: tachycardia , bradycardia • Blood pressure: high , low

  16. ECG on admission: Anterior ST segment elevation

  17. Thrombolysis

  18. Importance of time to reperfusionin patients undergoing PPCI for STEMI NCDR - National Cardiovascular Data Registry (USA) Cannon CP. JAMA 2000;283:2941 ;; Rathore SS. BMJ 2009;338:b1807

  19. Importance of time to reperfusionin patients given fibrinolysis for STEMI NCDR - National Cardiovascular Data Registry (USA) Cannon CP. JAMA 2000;283:2941 ;; Rathore SS. BMJ 2009;338:b1807

  20. Time to thrombolysis and 35-day mortality

  21. STEMI – time is muscle

  22. Reperfusion Therapy • Primary Percutaneous Coronary Intervention (PPCI) – preferred! (especially in cardiogenic shock, heart failure, arrhythmia, late presentation) • Thrombolytic Therapy – Fibrinolysis – if early! • Tissue Plasminogen Activator (tPA) • Streptokinase • Risk of Bleeding → Contraindications: • History of Intracranial Hemorrhage • History of Ischemic Stroke within 3 months • Cerebral vascular malformation or intracranial malignancy • Suspected Aortic Dissection • Active bleeding or known bleeding diathesis • Significant closed-head or facial trauma within 3 months • Traumatic or prolonged (>10 min) cardiac resuscitation

  23. Coronary Angiogram 1 5 LAD 2 7 LCX 11 RCA 6 3 12 8 9 4 13 15 10 14

  24. Thrombolysis Angioplasty

  25. Isolated LAD Lesion

  26. Reperfusion Therapy • Primary Percutaneous Coronary Intervention (PPCI) – preferred! (especially in cardiogenic shock, heart failure, arrhythmia, late presentation) • Thrombolytic Therapy – Fibrinolysis – if early! • Tissue Plasminogen Activator (tPA) • Streptokinase • Risk of Bleeding → Contraindications: • History of Intracranial Hemorrhage • History of Ischemic Stroke within 3 months • Cerebral vascular malformation or intracranial malignancy • Suspected Aortic Dissection • Active bleeding or known bleeding diathesis • Significant closed-head or facial trauma within 3 months • Traumatic or prolonged (>10 min) cardiac resuscitation

  27. TIMI grade 3 coronary flow is associated with improved survival

  28. Medical therapy (initial) • Oxygen (if O2 saturation < 95%) • Aspirin (300-325 mg) to be chewed • Sublingual Nitroglycerine (tablets or spray) • Morphine sulfate (2-4 mg) I.V. (intravenous) • Furosemide (40 mg) if pulmonary congestion • Beta blocker (5 mg metoprolol I.V., repeat X3) • High-dose statin (atorvastatin 80 mg orally) • Treat ventricular arrhythmia promptly (!) • Obtain blood for cardiac biomarkers (Troponin-T, CPK, hemoglobin, electrolytes, coagulation, kidney and liver function)

  29. Adding Clopidogrel to Aspirinin STEMI (COMMIT trial)

  30. TRITON – TIMI 38:patients with ACS undergoing PCI 13,608 patients (10,074 UA/NSTEMI ; 3,534 STEMI) Wiviott SD. TRITON – TIMI 38. N Engl J Med 2007;357:2001

  31. TRITON – TIMI 38:patients with STEMI undergoing PCI

  32. K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke) 18,624 patients (10,174 UA/NSTEMI ; 8,430 STEMI) 13 12 11.7 Clopidogrel 11 10 9.8 9 Ticagrelor 8 7 Cumulative incidence (%) 6 5 4 NNT = 54 3 2 HR 0.84 (95% CI 0.77–0.92), p=0.0003 1 0 0 60 120 180 240 300 360 Days after randomisation No. at risk 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Ticagrelor 9,291 8,521 8,362 8,124 6,743 5,096 4,047 Clopidogrel K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval Wallentin et al. NEJM 2009;361:1045-57

  33. 15% RRR

  34. Medical therapy (advanced) • 2ndantiplatelet (ADP-receptor antagonist) • Prasugrel, Clopidogrel, Ticagrelor • Anticoagulant therapy • Unfractionated heparin (4000-5000 units) I.V. • Glycoprotein IIb/IIIa inhibitors, I.V. (provisional) • Tirofiban (Aggrastat) • Eptifibatide (Integrilin) • Bivalirudin (in patients undergoing PPCI) • Low-molecular weight heparin (LMWH) – for patients not managed by PPCI / thrombolysis • Enoxaparin, Fondaparinux

  35. TIMI risk score for STEMI

  36. MI complications: Heart Failure • Dilation of the ventricle – “remodeling” • Increased wall stress • Reduced ejection fraction • Reduced functional capacity • Fluid overload (pulmonary congestion, peripheral edema, pleural effusion) • Look for Mitral Regurgitation (MR) • Therapy: ACE inhibitors, Beta blockers, spironolactone, diuretics, digoxin

  37. Impact of left ventricular functionon survival following MI Volpi A. GISSI-2 database. Circulation 1993;88:416

  38. MI complications: Arrhythmias • Ventricular tachycardia / fibrillation • Prompt DC shock • Bradycardia: • Sinus bradycardia , AV block – inferior MI • Atropin, Dopamine, Pacemaker • Tachycardia: • Sinus tachycardia • Atrial fibrillation • Treat heart failure

  39. MI complications: Pericarditis • Acute post MI pericarditis • Anti-inflammatory drugs, NSAID • Dressler syndrome • Anti-inflammatory drugs, steroids

  40. Cardiac Rupture Syndrmes Complicating STEMI Ventricular Septal Rupture – VSD with Rt. To Lt. Shunt Free Wall Rupture – Tamponade with Shock Papillary Muscle Rupture – with Severe Mitral Regurgitation

  41. MI complications: Rupture • Intra-aortic balloon pump (IABP) • If tamponade – prompt pericardiocentesis • Urgent surgery

  42. Therapy on discharge • Healthy life-style • Aspirin • 2ndantiplatelet • ACE-inhibitor • Beta-blocker • Statin (high dose) • Cardiac rehabilitation • Risk factor control (smoking, diabetes, hypertension, obesity, hyperlipidemia, etc.)

  43. Trends in in-hospital drug therapy over 10 years: following the guidlines Data from ACSIS: Acute Coronary Syndrome Israeli Survey

More Related